Pages that link to "Q28259350"

The following pages link to MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma (Q28259350):

Displaying 14 items.

• High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time (Q28536347) ‎ (← links)
• Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. (Q34023497) ‎ (← links)
• Monoclonal antibodies in gynecological cancer: a critical point of view (Q35659915) ‎ (← links)
• MUC1 drives c-Met-dependent migration and scattering. (Q36484469) ‎ (← links)
• The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. (Q36544576) ‎ (← links)
• Massive transcranial parotid pleomorphic adenoma: recurrence after 30 years (Q36857911) ‎ (← links)
• Vaccine-based clinical trials in ovarian cancer (Q37892583) ‎ (← links)
• Monoclonal antibodies therapies for ovarian cancer (Q38078400) ‎ (← links)
• The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression. (Q38100999) ‎ (← links)
• Therapeutic vaccines for ovarian cancer (Q38117024) ‎ (← links)
• Exploring the role and diversity of mucins in health and disease with special insight into non-communicable diseases (Q38560347) ‎ (← links)
• Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. (Q39063057) ‎ (← links)
• Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance (Q79972618) ‎ (← links)
• Pre-clinical safety evaluation of heat shock protein 65-MUC1 peptide fusion protein (Q80546286) ‎ (← links)